[ad_1]
Revenue of the US pharmaceutical company Gilead Sciences increased 17% in the third quarter, supported by sales of the antiviral drug remdesivir, the first and only officially approved treatment by the United States for the treatment of hospitalized patients with Covid-19, Reuters reports.
Read also: Adriana Săftoiu SPRAY NLP lists: People with no minimal culture, but knew how to talk to the leader’s coat
Remdesivir generated sales of $ 873 million in the September 30th quarter.
Analysts anticipated that Gilead would make an even greater profit of $ 960 million, according to data from IBES Refinitive.
Remdesivir, which is administered intravenously, was approved by the US health authorities last week. However, the drug has been available on the US market since May, with an emergency use authorization for the treatment of patients with Covid-19.
.
[ad_2]
Source link
